Intranodal Antitumor Immunocyte Infiltration in Node-negative Gastric Cancers

Size: px
Start display at page:

Download "Intranodal Antitumor Immunocyte Infiltration in Node-negative Gastric Cancers"

Transcription

1 Vol. 6, , July 2000 Clinical Cancer Research 2611 Advances in Brief Intranodal Antitumor Immunocyte Infiltration in Node-negative Gastric Cancers Sumiya Ishigami, 1 Shoji Natsugoe, Shuichi Hokita, Che Xiangming, Kuniaki Aridome, Hirofumi Iwashige, Koki Tokuda, Akihiro Nakajo, Futoshi Miyazono, and Takashi Aikou First Department of Surgery, Kagoshima University School of Medicine, Kagoshima , Japan Abstract The status and role of immunocytes and dendritic cells in regional lymph nodes in patients with gastric cancer are examined in this study. Forty-nine patients with gastric cancer who underwent curative resection were enrolled in the present study. These patients had no lymph node metastases according to a histological examination. The infiltration of natural killer (NK) cells, dendritic cells, and MIB-1-positive immunocytes was investigated. Based on the Japanese Classification of Gastric Carcinoma, regional lymph nodes were divided into three compartments: (a) compartment 1 (lymph node station numbers 1 6); (b) compartment 2 (lymph node station numbers 7 12); and (c) compartment 3 (lymph node station numbers 14 and 16). Dendritic cells and MIB-1- positive immunocytes infiltrated compartment 1 lymph nodes in increased numbers compared with the lymph nodes of compartments 2 or 3 (P < 0.05). Conversely, intranodal NK cell infiltration did not differ significantly among the three compartments. The incidence of intranodal dendritic and MIB-1-positive cell infiltration in patients with submucosal gastric cancer was significantly higher than in patients with tumors that invaded beyond the muscularis propria. The decreased expression of these immunological markers correlated well with recurrent disease, regardless of tumor depth. The immunocyte level is higher in lymph nodes near the primary tumor (compartment 1) than in those that are distant from the tumor (compartments 2 and 3). This pertains to all three markers, i.e., NK, dendritic, and MIB-1-positive cells. Unlike dendritic and MIB-1-positive cells, intratumoral infiltration of NK cells did not correlate well with either lymph node compartment or the depth of tumor invasion. The Received 10/21/99; revised 3/28/00; accepted 3/30/00. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. 1 To whom requests for reprints should be addressed, at First Department of Surgery, Kagoshima University School of Medicine, Sakuragaoka, Kagoshima , Japan. Phone: ; Fax: ; ishiga@med2.kufm.kagoshima-u.ac.jp. Table 1 Patient profile Gender Male 33 Female 16 Age (yr) Extension of lymphadenectomy D1 18 D2 27 D3 4 Number of resected nodes Operation Total 17 Proximal 6 Distal 26 Recurrence Yes 8 No 41 degree of NK cell infiltration may be directly associated with antitumor effects, especially in compartment 1. A decrease in all three markers is associated with tumor. Introduction Regional lymph nodes play an important role in the immunodefense against cancer cells and are considered the first line of defense against metastasis by the lymphatic route, which is the principle route of metastasis (1, 2). Because regional lymph nodes are frequent sites of metastasis in gastric carcinoma, surgical removal can control distant spread of tumor. Although the question of whether or not lymph node resection reduces the efficacy of the regional immune system cannot be answered at present, the prophylactic removal of lymph nodes that are not affected by metastasis probably affects the immune defenses (3, 4). The advent of immunological exploration of immunocytes has revealed detailed information about the properties of tumorinfiltrating immunocytes (5 7). Therefore, the relationship between tumor-infiltrating immunocytes and clinicopathological features has been studied. Dendritic cells serve as accessory cells that present antigens to sensitized T cells (5). Because these cells present antigens and stimulate CTLs (8 10), the density of dendritic cells is associated with the local immunity of CTLs (11, 12). NK 2 cells are also antitumor effectors that act without recognizing the HLA antigen. NK cells attack tumor cells in a manner different from that of CTLs (13 15). MIB-1 is an antigen that recognizes intracellular substances in proliferating cells and is used to determine the degrees of immunocyte activation and proliferation, especially those of lymphoma cells 2 The abbreviations used are: NK, natural killer; LI, labeling index.

2 2612 Lymph Node Immunity in Gastric Cancer Fig. 1 Lymph node station numbers according to the Japanese classification of macroscopic appearance of gastric cancer. Compartment 1 lymph node station numbers: 1, right paracardial lymph nodes; 3, lesser curvature lymph nodes; 4d, lymph nodes along the right gastroepiploic artery; 6, infrapyloric lymph nodes. Compartment 2 lymph node station numbers: 7, lymph nodes along the left gastric artery; 8a, lymph nodes along the common hepatic artery; 9, lymph nodes along the celiac artery; 10, lymph nodes of the splenic hilum; 11, splenic lymph nodes; 12, hepatoduodenal lymph nodes. Compartment 3 lymph node station numbers: 14, lymph nodes along the supermesenteric vessel; 16, paraaortic lymph nodes. (16, 17). MIB-1-positive immunocytes are considered to be stimulated immunocytes after receiving antigenic information. The intranodal infiltration of immunological effectors in gastrointestinal cancer has been demonstrated (18). Here we investigate local intratumoral immunocyte status in regional lymph nodes using intranodal NK cell and dendritic cell infiltration as well as the MIB-1-positive cell LI as markers in patients with node-negative gastric cancer. Furthermore, we examined the relationship between the expression of these immunological effector cells and clinicopathological findings. Patients and Methods Patients. A total of 49 patients with node-negative gastric cancer who underwent curative resection with lymphadenectomy in the First Department of Surgery, Kagoshima University Hospital between 1988 and 1998 participated in the current study. The age range of the 33 male and 16 female patients was from years (mean age, 48 years). Distal gastrectomy was performed in 26 patients, total gastrectomy was performed in 17 patients, and proximal gastrectomy was performed in 6 patients. All of the patients received no preoperative chemotherapy, underwent curative resection, and had no lymph node metastasis by histological examination. Eight (14%) patients died of recurrent gastric cancer [six with hepatic metastases, one with peritoneal metastases, one with lymph node metastases, and one with cachexia (Table 1)]. Microscopic Examination. The number of extirpated lymph nodes per patient ranged from 10 75, with a median value of 32. Resected lymph nodes were divided into three lymph node compartments according to the Japanese Classification of Gastric Carcinoma (Ref. 19; Fig. 1). A total of 1220 lymph nodes were examined as follows: (a) 156 of lymph node station number 1; (b) 358 of lymph node station number 3; (c) 178 of lymph node station number 4d; (d) 32 of lymph node station number 6; (e) 150 of lymph node station number 7; (f) 106 of lymph node station number 8a; (g) 73 of lymph node station number 9; (h) 49 of lymph node station number 10; (i) 28 of lymph node station number 11; (j) 34 of lymph node station number 12; (k) 13 of lymph node station number 14; and (l) 43 of lymph node station number 16. Lymph node sections were fixed in 10% formalin and embedded in paraffin. Routinely processed and H&E-stained sections were evaluated. Approximately 2000 lymphocytes per sample and field were examined under high-power ( 400) magnification. Dendritic and NK cell infiltration was examined by immunochemical staining. Dendritic cells were detected using S-100 protein (DAKO, Denmark) at a dilution of 1:200 (20), and

3 Clinical Cancer Research 2613 Fig. 2 a, CD57-positive lymphocytes are identified ( 200). b, diffuse dendritic cell infiltrate is present ( 200). c, sporadic MIB-1-positive lymphocytes are present ( 200).

4 2614 Lymph Node Immunity in Gastric Cancer Fig. 3 Distribution of intranodal NK cell values. No significant compartment difference is evident. CD57 (Immunotech, France) was used for detection of NK cells at a dilution of 1:50 (21). Ki67-positive immunocytes were evaluated by using MIB-1 antibody (Immunotech France; Ref. 22). The antibody was diluted at 1:500 and reacted overnight, and then primary antibodies were visualized using a streptavidin-biotin-peroxidase supersensitive kit (avidin-biotin complex method). A normal prostate gland and nerve tissue were used as positive controls for CD57 and S-100, respectively. The immunohistochemical expression of NK cells, dendritic cells, and MIB-1-positive immunocytes was evaluated by two independent observers (S. I. and S. N.). Ten representative fields were examined, and a total of 2000 lymphocytes (200 lymphocytes/field) were counted under a microscope with using highpower ( 400) magnification (20, 21). When evaluating immunocytic infiltration, dendritic cells and MIB-1-positive pericortical and intramedulary immunocytes were excluded because most of these immunocytes were related to B lymphocytes. We also examined the correlation between the degree of infiltration of the three immunocytes and the clinicopathological findings, retrospectively. Statistical Evaluation. Clinicopathological factors were examined using the 2 and t test. A P of less than 0.05 was considered statistically significant. Results NK cells were distributed homogeneously throughout the lymph nodes, but dendritic cells and MIB-1-positive immunocytes were present mainly in the cortex and paracortical areas (Fig. 2, a c). The incidence of NK cells, dendritic cells, and MIB-1-positive immunocytes in each compartment is shown in Figs. 3, 4, and 5. Although dendritic cells and MIB-1-positive cells were often found in the germinal center of the primary lymph follicles, they were not counted because they contained mainly activated B lymphocytes. The cell density varied from % (average, 24.0%) for dendritic cells, from 0 4.3% (average, 0.7%) for NK cells, and from 0 32% (average, 4.1%) for MIB-1-positive cells. The mean density of NK cell infiltration in compartments 1, 2, and 3 was 0.5%, 0.4%, and 0.4%, respectively. No significant differences among the three compartments were evident. However, the density of dendritic cell infiltration in compartment 1 was 42%, which was significantly higher than the infiltration in compartments 2 and 3 (P 0.05). In addition, the percentage of MIB-1-positive cells (6.1%) in compartment 1 was significantly higher than that in compartments 2 (3.3%) and 3 (0.5%; P 0.01). The intranodal NK, dendritic, and MIB-1-positive cell values in patients with submucosal cancer were 0.3%, 50%, and 11%, respectively. On the other hand, in patients with tumor invasion beyond the muscularis propria, the values were 0.4%, 28%, and 2.7%, respectively. Thus, dendritic and MIB-1-positive cells differed significantly between submucosal cancer and tumors reaching beyond the muscularis propria (P 0.05; Table 2). The eight patients who died of recurrent gastric cancer had infiltration values of 0.07%, 24%, and 3.6% for NK, dendritic, and MIB-1-positive cells in compartment 1. The level of ex-

5 Clinical Cancer Research 2615 Fig. 4 Distribution of intranodal dendritic cell values. Significant compartment difference is present. Fig. 5 Distribution of intranodal MIB-1-positive cell values. Significant compartment difference is present. pression of these immunological markers in patients with recurrent disease was significantly lower than that in patients showing no (Table 3). When the gastric tumor was confined to the t2 depth of invasion, the amount of dendritic cell and NK cell infiltration differed significantly between patients with and without (Table 4). Discussion Clinical and experimental data have indicated that the immunological balance might be disturbed by lymphadenectomy because immunocytes in regional lymph nodes actually function as antitumor effector cells. Some authors have even

6 2616 Lymph Node Immunity in Gastric Cancer Table 2 NK cell, dendritic cell, and MIB-1-positive lymphocyte infiltration according to the depth of invasion Depth of tumor invasion sm (n 16) a mp/ss (n 33) P NK cell infiltration NS b Dendritic cell infiltration MIB-1 LI (%) a sm, submucosa; mp, muscularis propria; ss, subserosa. b NS, not significant. Table 4 NK cell, dendritic cell, and MIB-1-positive lymphocyte infiltration in patients with or without confined to the depth of invasion t2 Patients without (n 21) Patients with (n 6) P NK cell infiltration Dendritic cell infiltration MIB-1 LI (%) NS a a NS, not significant. Table 3 NK cell, dendritic cell, and MIB-1-positive lymphocyte infiltration in patients with or without Patients without (n 41) Patients with (n 8) P NK cell infiltration Dendritic cell infiltration MIB-1 LI (%) reported that intratumoral infiltration of immunocytes reflects an immunological reaction to cancer (23, 24). However, the relationship between the antitumor effect of the regional lymph nodes against primary tumors and the role that lymphadenectomy plays has not been fully defined. In the present study, we attempted to examine the effect of intranodal infiltration of lymphocytes using three distinctive immunological cellular markers in patients with node-negative gastric cancer. The presence and clinical significance of lymph node micrometastasis have been elucidated by immunohistochemical and genetic methods (25, 26). Some of our patients probably harbored such metastases in these series. We attempted to study whether or not lymph node micrometastasis can be checked by immunocytes. We report that perigastric nodes contained more infiltrating dendritic and MIB-1-positive cells in compartment 1 than in compartments 2 and 3. This finding is in agreement with the notion that regional lymph nodes serve as a repository of dendritic cells that connect the primary tumor to distant lymph nodes (18). Moreover, these findings suggest that intragastric stimulation against tumors is reflected in the lymph nodes of compartment 1 because such stimulation may become weaker as the distance from the primary tumor increases. Similarly, NK, dendritic, and MIB-1-positive cells in each compartment showed similar tendencies. Unlike dendritic cells and MIB-1-positive cells, intranodal infiltration of NK cells did not correlate well with either lymph node compartment or the depth of tumor invasion. Because the decrease in NK cells was related to tumor, the degree of NK cell infiltration may be directly associated with antitumor effects, regardless of whether or not there is antigen stimulation. Lymph nodes with intact of compartment 1 possess the strongest antitumor activity. Therefore, in patients with early-stage gastric cancer, the lymph nodes should be preserved. The incidence of recurrent disease, irrespective of tumor depth, was low in patients with increased dendritic and NK cell infiltration. Moreover, hematogeneous metastasis was the most frequent mode in recurring gastric cancer. We have attempted to demonstrate the behavior of regional lymph nodes through NK, dendritic, and MIB-1-positive cell markers. Specifically, a decrease in these three markers was associated with tumor in patients with node-negative gastric cancer. These three markers may also exhibit antitumor effectors in regional lymph nodes. References 1. Marzo, A. L., Lake, R. A., Lo, D., Sherman, L., McWilliam, A., Nelson, D., Robinson, B. W., and Scott, B. Tumor antigens are constitutively presented in the draining lymph nodes. J. Immunol., 162: , Sakita, I., Monden, T., Nagaoka, H., Katsumoto, Y., Wakasugi, T., Tomita, N., Takeda, T., Kobayashi, T., Shimano, T., and Mori, T. Augmentation of antitumor immunity in regional lymph nodes by local immunotherapy. Biotherapy, 6: , Santin, A. D., and Parham, G. P. Routine lymph node dissection in the treatment of early stage cancer: are we doing the right thing? Gynecol. Oncol., 68: 1 3, Lores, B., Garcia-Estevez, J. M., and Arias, C. Lymph nodes and human tumors. Int. J. Mol. Med., 1: , Maehara, Y., Kabashima, A., Tokunaga, E., Hasuda, S., Oki, E., Kakeji, Y., Baba, H., and Sugimachi, K. Recurrences and relation to tumor growth potential and local immune response in node-negative advanced gastric cancer. Oncology (Basel), 56: , Yano, H., Kinuta, M., Tateishi, H., Nakano, Y., Matusi, S., Monden, T., Okamura, J., Sakai, M., and Okamoto, T. Mast cell infiltration around gastric cancer cells correlated with tumor angiogenesis and metastasis. Gastric Cancer, 2: 26 32, Saito, H., Tsujitani, S., Kondo, A., Ikeguchi, M., Maeta, M., and Kaibara, N. Combined analysis of tumour neoangiogenesis and local immune response in advanced gastric carcinoma. Oncol. Rep., 6: , Nussenzweig, M. C., Steinman, R. M., Gutchinov, B., and Cohn, Z. A. Dendritic cells are accessory cells for development of anti-trinitrophenyl cytotoxic T-lymphocytes. J. Exp. Med., 152: , Sunshine, G. H., Katz, D. R., and Feldmann, M. Dendritic cells induce T cell proliferation in response to synthetic antigens under Ir gene control. J. Exp. Med., 152: , Mulders, P., Tso, C. L., Gitlitz, B., Kaboo, R., Hinkel, A., Frand, S., Kiertscher, S., Roth, M. D., dekernion, J., Figlin, R., and Belldegrun, A. Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: implications for live kidney cancer vaccines. Clin. Cancer Res., 5: , Tsujitani, S., Kakeji, Y., Watanabe, A., Kohnoe, S., Maehara, Y., and Sugimachi, K. Infiltration of S-100 protein positive dendritic cells and peritoneal in advanced gastric cancer. Int. Surg., 77: , Tsujitani, S., Kakeji, Y., Maehara, Y., Sugimachi, K., and Kaibara, N. Dendritic cells prevent lymph node metastasis in patients with gastric cancer. In Vivo, 7: , Koba, F., Akiyoshi, T., and Tsuji, H. Natural killer cell activity in the perigastric lymph nodes from patients with gastric carcinoma or benign lesions. J. Clin. Lab. Immunol., 23: , 1987.

7 Clinical Cancer Research Nio, Y., Shiraishi, T., Imai, S., Tsubono, M., Morimoto, H., Tseng, C. C., and Tobe, T. The clinical status and histopathological factors affecting natural killer cells of peripheral blood lymphocytes in patients with gastric cancer. J. Clin. Lab. Immunol., 35: , Trinchieri, G., and Perussia, B. Human natural killer cells: biologic and pathologic aspects. Lab. Invest., 50: , Abele, M. C., Valente, G., Kerim, S., Navone, R., Onesti, P., Chiusa, L., Resegotti, L., and Palestro, G. Significance of cell proliferation index in assessing histological prognostic categories in Hodgkin s disease. An immunohistochemical study with Ki67 and MIB-1 monoclonal antibodies. Haematologica, 82: , Bierhoff, E., Vogel, J., Benz, M., Giefer, T., Wernert, N., and Pfeifer, U. Stromal nodules in benign prostatic hyperplasia. Eur. Urol., 29: , Tsujitani, S., Oka, A., Kondo, A., Ikeguchi, M., Maeta, M., and Kaibara, N. Infiltration of dendritic cells into regional lymph nodes in gastric cancer. Cancer (Phila.), 75: , Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma, 2nd English Edition. Gastric Cancer, 1: 10 24, Tsujitani, S., Kakeji, Y., Watanabe, A., Kohnoe, S., Maehara, Y., and Sugimachi, K. Infiltration of dendritic cells in relation to tumor invasion and lymph node metastasis in human gastric cancer. Cancer (Phila.), 66: , Coca, S., Perez-Piqueras, J., Martinez D., Colmenarejo, A., Saez, M. A., Vallejo, C., Martos, J. A., and Moreno, M. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer (Phila.), 79: , Broll, R., Mahlke, C., Best, R., Schimmelpenning, H., Strik, M. W., Schiedeck, T., Bruch, H. P., and Duchrow, M. Assessment of the proliferation index in gastric carcinomas with the monoclonal antibody MIB 1. J. Cancer Res. Clin. Oncol., 124: 49 54, Saito, H., Tsujitani, S., Kondo, A., Ikeguchi, M., Maeta, M., and Kaibara, N. Combined analysis of tumour neoangiogenesis and local immune response in advanced gastric carcinoma. Oncol. Rep., 6: , Ishigami, S., Aikou, T., Natsugoe, S., Hokita, S., Iwashige, H., Tokushige, M., and Sonoda, S. Prognostic value of HLA-DR expression and dendritic cell infiltration in gastric cancer. Oncology (Basel), 55: 65 69, Maehara, Y., Oshiro, T., Endo, K., Baba, H., Oda, S., Ichiyoshi, Y., Kohnoe, S., and Sugimachi, K. Clinical significance of occult micrometastasis lymph nodes from patients with early gastric cancer who died of. Surgery, 119: , Natsugoe, S., Mueller, J., Stein, H. J., Feith, M., Hofler, H., and Siewert, J. R. Micrometastasis and tumor cell microinvolvement of lymph nodes from esophageal squamous cell carcinoma: frequency, associated tumor characteristics, and impact on prognosis. Cancer (Phila.), 83: , 1998.

Endoscopic mucosal resection for treatment of early gastric cancer

Endoscopic mucosal resection for treatment of early gastric cancer Gut 2001;48:225 229 225 Endoscopic mucosal resection for treatment of early gastric cancer H Ono, H Kondo, T Gotoda, K Shirao, H Yamaguchi, D Saito, K Hosokawa, T Shimoda, S Yoshida Department of Endoscopy

More information

Report series: General cancer information

Report series: General cancer information Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for

More information

Do we have enough evidence for expanding the indications of ESD for EGC?

Do we have enough evidence for expanding the indications of ESD for EGC? Online Submissions: http://www.wjgnet.com/1007-9327office wjg@wjgnet.com doi:10.3748/wjg.v17.i21.2597 World J Gastroenterol 2011 June 7; 17(21): 2597-2601 ISSN 1007-9327 (print) ISSN 2219-2840 (online)

More information

Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer

Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer J.-L. Zhang, Q. Yao, J.-H. Chen,Y. Wang, H. Wang, Q. Fan, R. Ling, J. Yi and L. Wang Xijing Hospital Vascular Endocrine

More information

How to report Upper GI EMR/ESD specimens

How to report Upper GI EMR/ESD specimens Section of Pathology and Tumour Biology How to report Upper GI EMR/ESD specimens Dr.H.Grabsch Warning. Most of the criteria, methodologies, evidence presented in this talk are based on studies in early

More information

Adiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka

Adiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka Adiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka Neoadiuvant and adiuvant therapy for advanced gastric cancer Franco Roviello, IT Neoadjuvant and adjuvant therapy for advanced

More information

Cancer of the Cardia/GE Junction: Surgical Options

Cancer of the Cardia/GE Junction: Surgical Options Cancer of the Cardia/GE Junction: Surgical Options Michael A Smith, MD Associate Chief Thoracic Surgery Center for Thoracic Disease St Joseph s Hospital and Medical Center Phoenix, AZ Michael Smith, MD

More information

The Royal Marsden. Surgery for Gastric and GE Junction Cancer: primary palliative where and when? William Allum

The Royal Marsden. Surgery for Gastric and GE Junction Cancer: primary palliative where and when? William Allum The Royal Marsden Surgery for Gastric and GE Junction Cancer: primary palliative where and when? William Allum Any surgeon can cure Surgeon - dependent No surgeon can cure EMR D2 GASTRECTOMY H N SN. WEDGE

More information

Tumor Budding as a Useful Prognostic Marker in T1-Stage Squamous Cell Carcinoma of the Esophagus

Tumor Budding as a Useful Prognostic Marker in T1-Stage Squamous Cell Carcinoma of the Esophagus 2013;108:42 46 Tumor Budding as a Useful Prognostic Marker in T1-Stage Squamous Cell Carcinoma of the Esophagus HITOSHI TERAMOTO, MD, 1 * MASAHIKO KOIKE, MD, PhD, 1 CHIE TANAKA, MD, PhD, 1 SUGURU YAMADA,

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: adoptive_immunotherapy 11/1993 3/2016 3/2017 3/2016 Description of Procedure or Service The spontaneous regression

More information

What is Cancer? Cancer is a genetic disease: Cancer typically involves a change in gene expression/function:

What is Cancer? Cancer is a genetic disease: Cancer typically involves a change in gene expression/function: Cancer is a genetic disease: Inherited cancer Sporadic cancer What is Cancer? Cancer typically involves a change in gene expression/function: Qualitative change Quantitative change Any cancer causing genetic

More information

How to treat early gastric cancer. Surgery

How to treat early gastric cancer. Surgery How to treat early gastric cancer Surgery Mark I. van Berge Henegouwen Department of Surgery, AMC, Amsterdam Director upper GI surgical unit Academic Medical Center Upper GI surgery at AMC 100 oesophagectomies

More information

Update on Mesothelioma

Update on Mesothelioma November 8, 2012 Update on Mesothelioma Intro incidence and nomenclature Update on Classification Diagnostic specimens Morphologic features Epithelioid Histology Biphasic Histology Immunohistochemical

More information

A912: Kidney, Renal cell carcinoma

A912: Kidney, Renal cell carcinoma A912: Kidney, Renal cell carcinoma General facts of kidney cancer Renal cell carcinoma, a form of kidney cancer that involves cancerous changes in the cells of the renal tubule, is the most common type

More information

Learning Luncheon 7: Endoscopic Mucosal Resection: When, Where and How?

Learning Luncheon 7: Endoscopic Mucosal Resection: When, Where and How? Endoscopic Mucosal Resection (EMR): When, Where, and Charles J. Lightdale, MD Columbia University New York, NY Endoscopic Mucosal Resection (EMR) EMR developed for removal of sessile or flat neoplasms

More information

THYROID CANCER. I. Introduction

THYROID CANCER. I. Introduction THYROID CANCER I. Introduction There are over 11,000 new cases of thyroid cancer each year in the US. Females are more likely to have thyroid cancer than men by a ratio of 3:1, and it is more common in

More information

Oncos Therapeutics: ONCOS THERAPEUTICS Personalized Cancer Immunotherapy. March 2015. Antti Vuolanto, COO and co-founder

Oncos Therapeutics: ONCOS THERAPEUTICS Personalized Cancer Immunotherapy. March 2015. Antti Vuolanto, COO and co-founder Oncos Therapeutics: Personalized Cancer Immunotherapy ONCOS THERAPEUTICS Personalized Cancer Immunotherapy March 2015 Antti Vuolanto, COO and co-founder 1 History of Oncos Therapeutics 2002 2007 2009 Research

More information

The utility of endoscopic ultrasonography and endoscopy in the endoscopic mucosal resection of early gastric cancer

The utility of endoscopic ultrasonography and endoscopy in the endoscopic mucosal resection of early gastric cancer Gut 1999;45:599 604 599 The utility of endoscopic ultrasonography and endoscopy in the endoscopic mucosal resection of early gastric cancer S Ohashi, K Segawa, S Okamura, M Mitake, H Urano, M Shimodaira,

More information

specific B cells Humoral immunity lymphocytes antibodies B cells bone marrow Cell-mediated immunity: T cells antibodies proteins

specific B cells Humoral immunity lymphocytes antibodies B cells bone marrow Cell-mediated immunity: T cells antibodies proteins Adaptive Immunity Chapter 17: Adaptive (specific) Immunity Bio 139 Dr. Amy Rogers Host defenses that are specific to a particular infectious agent Can be innate or genetic for humans as a group: most microbes

More information

Current Status of Esophageal Cancer Treatment

Current Status of Esophageal Cancer Treatment Cancer Current Status of Esophageal Cancer Treatment JMAJ 46(11): 497 503, 2003 Hiroyasu MAKUUCHI Professor and Chairman, Department of Surgery, Tokai University School of Medicine Abstract: The diagnosis

More information

Avastin: Glossary of key terms

Avastin: Glossary of key terms Avastin: Glossary of key terms Adenocarcinoma Adenoma Adjuvant therapy Angiogenesis Anti-angiogenics Antibody Antigen Avastin (bevacizumab) Benign A form of carcinoma that originates in glandular tissue.

More information

Endoscopic Submucosal Dissection (E.S.D.) vs. Endoscopic Mucosal Resection (E.M.R.) in Colombia. Advocating E.M.R.

Endoscopic Submucosal Dissection (E.S.D.) vs. Endoscopic Mucosal Resection (E.M.R.) in Colombia. Advocating E.M.R. Controversies in Gastroenterology Endoscopic Submucosal Dissection (E.S.D.) vs. Endoscopic Mucosal Resection (E.M.R.) in Colombia. Advocating E.M.R. Raúl Cañadas Garrido, MD. 1 1 Internist-Gastroenterologist.

More information

Immuno-Oncology Therapies to Treat Lung Cancer

Immuno-Oncology Therapies to Treat Lung Cancer Immuno-Oncology Therapies to Treat Lung Cancer What you need to know ONCHQ14NP07519 Introduction: Immuno-oncology represents an innovative approach to cancer research that seeks to harness the body s own

More information

Ensemble Learning of Colorectal Cancer Survival Rates

Ensemble Learning of Colorectal Cancer Survival Rates Ensemble Learning of Colorectal Cancer Survival Rates Chris Roadknight School of Computing Science University of Nottingham Malaysia Campus Malaysia Chris.roadknight@nottingham.edu.my Uwe Aickelin School

More information

HER2 Status: What is the Difference Between Breast and Gastric Cancer?

HER2 Status: What is the Difference Between Breast and Gastric Cancer? Ask the Experts HER2 Status: What is the Difference Between Breast and Gastric Cancer? Bharat Jasani MBChB, PhD, FRCPath Marco Novelli MBChB, PhD, FRCPath Josef Rüschoff, MD Robert Y. Osamura, MD, FIAC

More information

Malignant Lymphomas and Plasma Cell Myeloma

Malignant Lymphomas and Plasma Cell Myeloma Malignant Lymphomas and Plasma Cell Myeloma Dr. Bruce F. Burns Dept. of Pathology and Lab Medicine Overview definitions - lymphoma lymphoproliferative disorder plasma cell myeloma pathogenesis - translocations

More information

EMR Can anyone do this?

EMR Can anyone do this? EMR Can anyone do this? Norio Fukami, MD University of Colorado Piecemeal resection? 1 Endoscopic mucosal resection (EMR) and Endoscopic submucosal dissection (ESD) Endoscopic removal of premalignant or

More information

Metastatic Renal Cell Carcinoma: Staging and Prognosis of Three Separate Cases.

Metastatic Renal Cell Carcinoma: Staging and Prognosis of Three Separate Cases. Metastatic Renal Cell Carcinoma: Staging and Prognosis of Three Separate Cases. Abstract This paper describes the staging, imaging, treatment, and prognosis of renal cell carcinoma. Three case studies

More information

Kidney Cancer OVERVIEW

Kidney Cancer OVERVIEW Kidney Cancer OVERVIEW Kidney cancer is the third most common genitourinary cancer in adults. There are approximately 54,000 new cancer cases each year in the United States, and the incidence of kidney

More information

An Introduction To Immunotherapy And The Promise Of Tissue Phenomics

An Introduction To Immunotherapy And The Promise Of Tissue Phenomics An Introduction To Immunotherapy And The Promise Of Tissue Phenomics INSIDE: n The Potential of Immunotherapy n Towards an Understanding of Immunotherapy n Current Approaches to Immunotherapy n The Immunotherapy

More information

Lymph Nodes and Cancer What is the lymph system?

Lymph Nodes and Cancer What is the lymph system? Lymph Nodes and Cancer What is the lymph system? Our bodies have a network of lymph vessels and lymph nodes. (Lymph is pronounced limf.) This network is a part of the body s immune system. It collects

More information

The Immune System: A Tutorial

The Immune System: A Tutorial The Immune System: A Tutorial Modeling and Simulation of Biological Systems 21-366B Shlomo Ta asan Images taken from http://rex.nci.nih.gov/behindthenews/uis/uisframe.htm http://copewithcytokines.de/ The

More information

Stomach (Gastric) Cancer. Prof. M K Mahajan ACDT & RC Bathinda

Stomach (Gastric) Cancer. Prof. M K Mahajan ACDT & RC Bathinda Stomach (Gastric) Cancer Prof. M K Mahajan ACDT & RC Bathinda Gastric Cancer Role of Radiation Layers of the Stomach Mucosa Submucosa Muscularis Serosa Stomach and Regional Lymph Nodes Stomach and Regional

More information

OBJECTIVES By the end of this segment, the community participant will be able to:

OBJECTIVES By the end of this segment, the community participant will be able to: Cancer 101: Cancer Diagnosis and Staging Linda U. Krebs, RN, PhD, AOCN, FAAN OCEAN Native Navigators and the Cancer Continuum (NNACC) (NCMHD R24MD002811) Cancer 101: Diagnosis & Staging (Watanabe-Galloway

More information

Surgical Management of Papillary Microcarcinoma 趙 子 傑 長 庚 紀 念 醫 院 林 口 總 院 一 般 外 科

Surgical Management of Papillary Microcarcinoma 趙 子 傑 長 庚 紀 念 醫 院 林 口 總 院 一 般 外 科 Surgical Management of Papillary Microcarcinoma 趙 子 傑 長 庚 紀 念 醫 院 林 口 總 院 一 般 外 科 Papillary microcarcinoma of thyroid Definition latent aberrant thyroid occult thyroid carcinoma latent papillary carcinoma)

More information

YOUR LUNG CANCER PATHOLOGY REPORT

YOUR LUNG CANCER PATHOLOGY REPORT UNDERSTANDING YOUR LUNG CANCER PATHOLOGY REPORT 1-800-298-2436 LungCancerAlliance.org A GUIDE FOR THE PATIENT 1 CONTENTS What is a Pathology Report?...3 The Basics...4 Sections of a Pathology Report...7

More information

One out of every two men and one out of every three women will have some type of cancer at some point during their lifetime. 3

One out of every two men and one out of every three women will have some type of cancer at some point during their lifetime. 3 1. What is cancer? 2. What causes cancer?. What causes cancer? 3. Can cancer be prevented? The Facts One out of every two men and one out of every three women will have some type of cancer at some point

More information

Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma

Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma The Use of Kinase Inhibitors: Translational Lab Results Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma Sheelu Varghese, Ph.D. H. Richard Alexander, M.D.

More information

PANCREATIC AND PERIAMPULLARY TUMORS: PANCREATICODUODENECTOMY. Dr. Shailesh V. Shrikhande

PANCREATIC AND PERIAMPULLARY TUMORS: PANCREATICODUODENECTOMY. Dr. Shailesh V. Shrikhande PANCREATIC AND PERIAMPULLARY TUMORS: PANCREATICODUODENECTOMY Dr. Shailesh V. Shrikhande Associate Professor & Consultant Surgeon GI and HPB Surgical Oncology Tata Memorial Hospital, Mumbai INDIA HELICAL

More information

Smoking and misuse of certain pain medicines can affect the risk of developing renal cell cancer.

Smoking and misuse of certain pain medicines can affect the risk of developing renal cell cancer. Renal cell cancer Renal cell cancer is a disease in which malignant (cancer) cells form in tubules of the kidney. Renal cell cancer (also called kidney cancer or renal adenocarcinoma) is a disease in which

More information

LYMPHOMA. BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons

LYMPHOMA. BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons LYMPHOMA BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons Normal development of lymphocytes Lymphocyte proliferation and differentiation:

More information

PROTOCOL OF THE RITA DATA QUALITY STUDY

PROTOCOL OF THE RITA DATA QUALITY STUDY PROTOCOL OF THE RITA DATA QUALITY STUDY INTRODUCTION The RITA project is aimed at estimating the burden of rare malignant tumours in Italy using the population based cancer registries (CRs) data. One of

More information

A 70-year old Man with Pleural Effusion

A 70-year old Man with Pleural Effusion Mesothelioma Diagnosis: Pitfalls and Latest Updates S Klebe and DW Henderson Recommendations Indisputable malignant cells on cytomorphological criteria which demonstrate a mesothelial phenotype, which

More information

PRODYNOV. Targeted Photodynamic Therapy of Ovarian Peritoneal Carcinomatosis ONCO-THAI. Image Assisted Laser Therapy for Oncology

PRODYNOV. Targeted Photodynamic Therapy of Ovarian Peritoneal Carcinomatosis ONCO-THAI. Image Assisted Laser Therapy for Oncology PRODYNOV Targeted Photodynamic Therapy of Ovarian Peritoneal Carcinomatosis ONCO-THAI Image Assisted Laser Therapy for Oncology Inserm ONCO-THAI «Image Assisted Laser Therapy for Oncology» Inserm ONCO-THAI

More information

Ching-Yao Yang, Yu-Wen Tien

Ching-Yao Yang, Yu-Wen Tien Ching-Yao Yang, Yu-Wen Tien Division of General Surgery, Department of Surgery, National Taiwan University Hospital Oct-30-2010 Pancreatic NET have poorer prognosis when presence of liver metastases at

More information

Sentinel Lymph Node Mapping for Endometrial Cancer. Locke Uppendahl, MD Grand Rounds

Sentinel Lymph Node Mapping for Endometrial Cancer. Locke Uppendahl, MD Grand Rounds Sentinel Lymph Node Mapping for Endometrial Cancer Locke Uppendahl, MD Grand Rounds Endometrial Cancer Most common gynecologic malignancy in US estimated 52,630 new cases in 2014 estimated 8,590 deaths

More information

Sarcomatoid Renal Cell Carcinoma: Biologic Behavior, Prognosis, and Response to Combined Surgical Resection and Immunotherapy

Sarcomatoid Renal Cell Carcinoma: Biologic Behavior, Prognosis, and Response to Combined Surgical Resection and Immunotherapy Sarcomatoid Renal Cell Carcinoma: Biologic Behavior, Prognosis, and Response to Combined Surgical Resection and Immunotherapy By Thomas Cangiano, Joseph Liao, John Naitoh, Frederick Dorey, Robert Figlin,

More information

Current Status and Perspectives of Radiation Therapy for Breast Cancer

Current Status and Perspectives of Radiation Therapy for Breast Cancer Breast Cancer Current Status and Perspectives of Radiation Therapy for Breast Cancer JMAJ 45(10): 434 439, 2002 Masahiro HIRAOKA, Masaki KOKUBO, Chikako YAMAMOTO and Michihide MITSUMORI Department of Therapeutic

More information

Historical Basis for Concern

Historical Basis for Concern Androgens After : Are We Ready? Mohit Khera, MD, MBA Assistant Professor of Urology Division of Male Reproductive Medicine and Surgery Scott Department of Urology Baylor College of Medicine Historical

More information

Early Prostate Cancer: Questions and Answers. Key Points

Early Prostate Cancer: Questions and Answers. Key Points CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Early Prostate Cancer:

More information

7. Prostate cancer in PSA relapse

7. Prostate cancer in PSA relapse 7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined

More information

Locoregional & advanced esophagus or esophagogastric junction cancer

Locoregional & advanced esophagus or esophagogastric junction cancer Eloxatin (oxaliplatin) Prior Authorization Request (For Maryland Only) Send completed form to: Case Review Unit CVS/caremark Specialty Programs Fax: 866-249-6155 CVS/caremark administers the prescription

More information

Male. Female. Death rates from lung cancer in USA

Male. Female. Death rates from lung cancer in USA Male Female Death rates from lung cancer in USA Smoking represents an interesting combination of an entrenched industry and a clearly drug-induced cancer Tobacco Use in the US, 1900-2000 5000 100 Per Capita

More information

Osteosarcoma: treatment beyond surgery

Osteosarcoma: treatment beyond surgery Osteosarcoma: treatment beyond surgery Eric Chow, DVM DACVS Sue Downing, DVM DACVIM-Oncology Providing the best quality care and service for the patient, the client, and the referring veterinarian. Osteosarcoma

More information

Survival analysis of 220 patients with completely resected stage II non small cell lung cancer

Survival analysis of 220 patients with completely resected stage II non small cell lung cancer 窑 Original Article 窑 Chinese Journal of Cancer Survival analysis of 22 patients with completely resected stage II non small cell lung cancer Yun Dai,2,3, Xiao Dong Su,2,3, Hao Long,2,3, Peng Lin,2,3, Jian

More information

Luis D. Carcorze Soto, MD PGY-3

Luis D. Carcorze Soto, MD PGY-3 Luis D. Carcorze Soto, MD PGY-3 Peritoneal Surface Malignancies Peritoneum Patient Selection Operative Technique HIPEC EPIC Primary: Primary Peritoneal Carcinoma Malignant Peritoneal Mesothelioma Metastatic:

More information

Cancer is the leading cause of death for Canadians aged 35 to 64 and is also the leading cause of critical illness claims in Canada.

Cancer is the leading cause of death for Canadians aged 35 to 64 and is also the leading cause of critical illness claims in Canada. Underwriting cancer In this issue of the Decision, we provide an overview of Canadian cancer statistics and the information we use to make an underwriting decision. The next few issues will deal with specific

More information

Cancer and the immune system: can we beat cancer at its own game?

Cancer and the immune system: can we beat cancer at its own game? Cancer and the immune system: can we beat cancer at its own game? Andrew R. Haas, MD, PhD Assistant Professor of Medicine University of Pennsylvania Medical Center Philadelphia, Pa Why can t immune

More information

Oncological outcome of surgical treatment in 336 patients with renal cell carcinoma

Oncological outcome of surgical treatment in 336 patients with renal cell carcinoma 窑 Original Article 窑 Chinese Journal of Cancer Oncological outcome of surgical treatment in 336 patients with renal cell carcinoma Zhi Ling Zhang,2, Yong Hong Li,2, Yong Hong Xiong 3, Guo Liang Hou,2,

More information

Frequently Asked Questions About Ovarian Cancer

Frequently Asked Questions About Ovarian Cancer Media Contact: Gerri Gomez Howard Cell: 303-748-3933 gerri@gomezhowardgroup.com Frequently Asked Questions About Ovarian Cancer What is ovarian cancer? Ovarian cancer is a cancer that forms in tissues

More information

The Ontario Cancer Registry moves to the 21 st Century

The Ontario Cancer Registry moves to the 21 st Century The Ontario Cancer Registry moves to the 21 st Century Rebuilding the OCR Public Health Ontario Grand Rounds Oct. 14, 2014 Diane Nishri, MSc Mary Jane King, MPH, CTR Outline 1. What is the Ontario Cancer

More information

Lymphoma Diagnosis and Classification

Lymphoma Diagnosis and Classification Lymphoma Diagnosis and Classification By Atef Shrit, MD, Pathology B- and T/NK-cell lymphomas are clonal neoplasms of immature and mature B-lymphocytes, T-lymphocytes or natural killer cells at various

More information

Radiation Therapy in the Treatment of

Radiation Therapy in the Treatment of Lung Cancer Radiation Therapy in the Treatment of Lung Cancer JMAJ 46(12): 537 541, 2003 Kazushige HAYAKAWA Professor and Chairman, Department of Radiology, Kitasato University School of Medicine Abstract:

More information

Pathologic Assessment Of The Breast And Axilla After Preoperative Therapy

Pathologic Assessment Of The Breast And Axilla After Preoperative Therapy Pathologic Assessment Of The Breast And Axilla After Preoperative Therapy W. Fraser Symmans, M.D. Associate Professor of Pathology UT M.D. Anderson Cancer Center Pathologic Complete Response (pcr) Proof

More information

Predictive Biomarkers for Tumor Immunotherapy: Are we ready for clinical implementation? Howard L. Kaufman Rush University

Predictive Biomarkers for Tumor Immunotherapy: Are we ready for clinical implementation? Howard L. Kaufman Rush University Predictive Biomarkers for Tumor Immunotherapy: Are we ready for clinical implementation? Howard L. Kaufman Rush University Changing Paradigms in Cancer Treatment Potential Uses of Biomarkers Adverse event

More information

Targeted Therapies in Lung Cancer

Targeted Therapies in Lung Cancer Targeted Therapies in Lung Cancer I Edited by: Simona Carnio Thoracic Oncology Division - St Luigi Hospital Orbassano (TO) - Italy Silvia Novello Department of Oncology - University of Torino - Italy Why

More information

Treatment and Surveillance of Non- Muscle Invasive Bladder Cancer

Treatment and Surveillance of Non- Muscle Invasive Bladder Cancer Treatment and Surveillance of Non- Muscle Invasive Bladder Cancer David Josephson, MD FACS Fellowship Director, Urologic Oncology and Robotic Surgery Program Staging Most important in risk assessment and

More information

Post-recurrence survival in completely resected stage I non-small cell lung cancer with local recurrence

Post-recurrence survival in completely resected stage I non-small cell lung cancer with local recurrence Post- survival in completely resected stage I non-small cell lung cancer with local J-J Hung, 1,2,3 W-H Hsu, 3 C-C Hsieh, 3 B-S Huang, 3 M-H Huang, 3 J-S Liu, 2 Y-C Wu 3 See Editorial, p 185 c A supplementary

More information

The Body s Defenses CHAPTER 24

The Body s Defenses CHAPTER 24 CHAPTER 24 The Body s Defenses PowerPoint Lectures for Essential Biology, Third Edition Neil Campbell, Jane Reece, and Eric Simon Essential Biology with Physiology, Second Edition Neil Campbell, Jane Reece,

More information

Combination Therapy After EMR/ESD for Esophageal Squamous Cell Carcinoma with Submucosal Invasion

Combination Therapy After EMR/ESD for Esophageal Squamous Cell Carcinoma with Submucosal Invasion Combination Therapy After EMR/ESD for Esophageal Squamous Cell Carcinoma with Submucosal Invasion 8 Ota M., Nakamura T. and Yamamoto M. Department of Surgery, Institute of Gastroenterology, Tokyo Women's

More information

SARCOMATOID DIFFERENTIATION IN RENAL CELL CARCINOMA: PROGNOSTIC IMPLICATIONS

SARCOMATOID DIFFERENTIATION IN RENAL CELL CARCINOMA: PROGNOSTIC IMPLICATIONS Clinical Urology International Braz J Urol Official Journal of the Brazilian Society of Urology SARCOMATOID DIFFERENTIATION IN RCC Vol. 31 (1): 101, January February, 2005 SARCOMATOID DIFFERENTIATION IN

More information

Medullary Renal Cell Carcinoma Case Report

Medullary Renal Cell Carcinoma Case Report Bahrain Medical Bulletin, Vol. 27, No. 4, December 2005 Medullary Renal Cell Carcinoma Case Report Mohammed Abdulla Al-Tantawi MBBCH, CABS* Abdul Amir Issa MBBCH, CABS*** Mohammed Abdulla MBBCH, CABS**

More information

Outcome of Early Cervical Carcinoma Treated by Wertheim Hysterectomy with Selective Postoperative Radiotherapy

Outcome of Early Cervical Carcinoma Treated by Wertheim Hysterectomy with Selective Postoperative Radiotherapy ORIGINAL ARTICLES 613 Outcome of Early Cervical Carcinoma Treated by Wertheim Hysterectomy with Selective Postoperative Radiotherapy S K Tay,*FAMS, MD, FRCOG, L K Tan,**MBBS, M Med (O & G), MRCOG Abstract

More information

New strategies in anticancer therapy

New strategies in anticancer therapy 癌 症 診 療 指 引 簡 介 及 臨 床 應 用 New strategies in anticancer therapy 中 山 醫 學 大 學 附 設 醫 院 腫 瘤 內 科 蔡 明 宏 醫 師 2014/3/29 Anti-Cancer Therapy Surgical Treatment Radiotherapy Chemotherapy Target Therapy Supportive

More information

Small Cell Lung Cancer

Small Cell Lung Cancer Small Cell Lung Cancer Types of Lung Cancer Non-small cell carcinoma (NSCC) (87%) Adenocarcinoma (38%) Squamous cell (20%) Large cell (5%) Small cell carcinoma (13%) Small cell lung cancer is virtually

More information

The TV Series. www.healthybodyhealthymind.com INFORMATION TELEVISION NETWORK

The TV Series. www.healthybodyhealthymind.com INFORMATION TELEVISION NETWORK The TV Series www.healthybodyhealthymind.com Produced By: INFORMATION TELEVISION NETWORK ONE PARK PLACE 621 NW 53RD ST BOCA RATON, FL 33428 1-800-INFO-ITV www.itvisus.com 2005 Information Television Network.

More information

Endoscopic Therapy for Early Esophageal Cancer: EMR and ESD

Endoscopic Therapy for Early Esophageal Cancer: EMR and ESD Endoscopic Therapy for Early Esophageal Cancer: EMR and ESD AATS Toronto April 26, 2014 Lorenzo Ferri MD PhD David S. Mulder Chair in Surgery Associate Professor of Surgery and Oncology Disclosures Olympus

More information

Ph.D. in Molecular Medicine

Ph.D. in Molecular Medicine Ph.D. in Molecular Medicine and Translational Research College of Medicine 1. Introduction: The College of Medicine, while consolidating on its undergraduate innovative educational programs, decided to

More information

1400 Telegraph Bloomfield Hills, MI 48302 248-334-6877-Phone number/248-334-6877-fax Number CANCER TREATMENT

1400 Telegraph Bloomfield Hills, MI 48302 248-334-6877-Phone number/248-334-6877-fax Number CANCER TREATMENT 1400 Telegraph Bloomfield Hills, MI 48302 248-334-6877-Phone number/248-334-6877-fax Number CANCER TREATMENT Learning that your pet has a diagnosis of cancer can be overwhelming. We realize that your pet

More information

Pancreatic Carcinoma Recurrence in the Remnant Pancreas after a Pancreaticoduodenectomy

Pancreatic Carcinoma Recurrence in the Remnant Pancreas after a Pancreaticoduodenectomy CASE REPORT Pancreatic Carcinoma Recurrence in the Remnant Pancreas after a Pancreaticoduodenectomy Raffaele Dalla Valle 1, Cristina Mancini 2, Pellegrino Crafa 2, Rodolfo Passalacqua 3 1 Department of

More information

H. Richard Alexander, Jr., M.D. Department of Surgery and The Greenebaum Cancer Center University of Maryland School of Medicine Baltimore, Md

H. Richard Alexander, Jr., M.D. Department of Surgery and The Greenebaum Cancer Center University of Maryland School of Medicine Baltimore, Md Major Advances in Cancer Prevention, Diagnosis and Treatment~ Why Mesothelioma Leads the Way H. Richard Alexander, Jr., M.D. Department of Surgery and The Greenebaum Cancer Center University of Maryland

More information

MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY

MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY MALIGNANT MESOTHELIOMA CLASSIFICATION MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY Sisko Anttila, MD, PhD Jorvi Hospital Laboratory of Pathology Helsinki University Hospital Espoo,

More information

Targeted Therapy What the Surgeon Needs to Know

Targeted Therapy What the Surgeon Needs to Know Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures

More information

Pathology of lung cancer

Pathology of lung cancer Pathology of lung cancer EASO COURSE ON LUNG CANCER AND MESOTHELIOMA DAMASCUS (SYRIA), MAY 3-4, 2007 Gérard ABADJIAN MD Pathologist Associate Professor, Saint Joseph University Pathology Dept. Hôtel-Dieu

More information

Evidence tabel Lokaal palliatieve behandelingen

Evidence tabel Lokaal palliatieve behandelingen Auteurs, jaartal Mate van bewijs Studie type Follow-up Populatie (incl. steekproef-grootte) Patienten kenmerken Interventie Controle Resultaten Conclusie Opmerkingen, commentaar Hartgrink, 2002 The Netherlands

More information

Understanding Metastatic Disease

Understanding Metastatic Disease Supported by an unrestricted educational grant from Pfizer Understanding Metastatic Disease Metastatic disease or metastases are phrases that mean the same as Secondary cancer. This means that the cancer

More information

Finding an Appropriate Treatment

Finding an Appropriate Treatment Focus on CME at the University of Toronto Early Detected Lung Cancer: Finding an Appropriate Treatment Thanks to modern technology, subcentimeter tumors are now being identified. As with other malignant

More information

Thursday, November 3, 2005

Thursday, November 3, 2005 Thursday, November 3, 2005 8:30-10:30 a. m. Gastric Tumors, Session 1 Chairman: P. Ruszniewski, Clichy, France 9:00-9:30 a. m. Working Group Sessions Pathology and Genetics Group leaders: G. Rindi, Parma,

More information

Primary -Benign - Malignant Secondary

Primary -Benign - Malignant Secondary TUMOURS OF THE LUNG Primary -Benign - Malignant Secondary The incidence of lung cancer has been increasing almost logarithmically and is now reaching epidemic levels. The overall cure rate is very low

More information

Department of BioScience Technology Chung Yuan Christian University 2015/08/13

Department of BioScience Technology Chung Yuan Christian University 2015/08/13 Department of BioScience Technology Chung Yuan Christian University 2015/08/13 Cancer Cells Cancer, the 1st leading cause of death, is an example of a disease that arises from abnormalities in cell function

More information

Avastin in breast cancer: Summary of clinical data

Avastin in breast cancer: Summary of clinical data Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading

More information

Analysis of the colorectal tumor microenvironment using integrative bioinformatic tools

Analysis of the colorectal tumor microenvironment using integrative bioinformatic tools MLECNIK Bernhard & BINDEA Gabriela Analysis of the colorectal tumor microenvironment using integrative bioinformatic tools INSERM U872, Jérôme Galon Team15: Integrative Cancer Immunology Cordeliers Research

More information

ENDOSCOPIC SUBMUCOSAL DISSECTION FOR THE TREATMENT OF EARLY ESOPHAGEAL AND GASTRIC CANCER - INITIAL EXPERIENCE OF A WESTERN CENTER

ENDOSCOPIC SUBMUCOSAL DISSECTION FOR THE TREATMENT OF EARLY ESOPHAGEAL AND GASTRIC CANCER - INITIAL EXPERIENCE OF A WESTERN CENTER CLINICS 2010;65(4):377-82 CLINICAL SCIENCE ENDOSCOPIC SUBMUCOSAL DISSECTION FOR THE TREATMENT OF EARLY ESOPHAGEAL AND GASTRIC CANCER - INITIAL EXPERIENCE OF A WESTERN CENTER Dalton Marques Chaves, I Fauze

More information

Title: Immunohistochemical staining of radixin and moesin in prostatic adenocarcinoma

Title: Immunohistochemical staining of radixin and moesin in prostatic adenocarcinoma Author's response to reviews Title: Immunohistochemical staining of radixin and moesin in prostatic adenocarcinoma Authors: Tanner L Bartholow (bartholow.tanner@medstudent.pitt.edu) Uma R Chandran (chandranur@msx.upmc.edu)

More information

BREAST CANCER PATHOLOGY

BREAST CANCER PATHOLOGY BREAST CANCER PATHOLOGY FACT SHEET Version 4, Aug 2013 This fact sheet was produced by Breast Cancer Network Australia with input from The Royal College of Pathologists of Australasia I m a nurse and know

More information

Update on thyroid cancer surveillance and management of recurrent disease. Minimally invasive thyroid surgery

Update on thyroid cancer surveillance and management of recurrent disease. Minimally invasive thyroid surgery Update on thyroid cancer surveillance and management of recurrent disease Minimally invasive thyroid surgery July 2006 Michael W. Yeh, MD Program Director, Endocrine Surgery Assistant Professor, David

More information

Loco-regional Recurrence

Loco-regional Recurrence Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer AGO AGO e. e. V. V. Loco-regional Recurrence Loco-regional Recurrence Version 2002: Brunnert / Simon Versions 2003 2012: Audretsch

More information

CHAPTER 14 STAGING AND REPORTING

CHAPTER 14 STAGING AND REPORTING CHAPTER 14 STAGING AND REPORTING Staging of Colorectal Cancer refers to the classification of the tumour according to the extent of spread in a manner that has a clinically useful correlation with prognosis.

More information

SUNY DOWNSTATE MEDICAL CENTER SURGERY GRAND ROUNDS February 28, 2013 VERENA LIU, MD ROSEANNA LEE, MD

SUNY DOWNSTATE MEDICAL CENTER SURGERY GRAND ROUNDS February 28, 2013 VERENA LIU, MD ROSEANNA LEE, MD SUNY DOWNSTATE MEDICAL CENTER SURGERY GRAND ROUNDS February 28, 2013 VERENA LIU, MD ROSEANNA LEE, MD Case Presentation 35 year old male referred from PMD with an asymptomatic palpable right neck mass PMH/PSH:

More information

MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY

MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY Sisko Anttila, MD, PhD Jorvi Hospital Laboratory of Pathology Helsinki University Hospital Espoo, Finland 2nd Nordic Conference on Applied

More information